Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2019

01-10-2019 | Mastectomy | Breast Oncology

Enhanced Recovery Minimizes Opioid Use and Hospital Stay for Patients Undergoing Mastectomy with Reconstruction

Authors: Caroline J. McGugin, MD, MSPH, Suzanne B. Coopey, MD, Barbara L. Smith, MD, PhD, Bridget N. Kelly, BA, Carson L. Brown, MS, Michele A. Gadd, MD, Kevin S. Hughes, MD, Michelle C. Specht, MD

Published in: Annals of Surgical Oncology | Issue 11/2019

Login to get access

Abstract

Background

This study examined the effects of an enhanced recovery program on inpatient opioid requirements and hospital length of stay (LOS) for mastectomy patients undergoing immediate reconstruction.

Methods

An enhanced recovery program for patients undergoing mastectomy with immediate tissue expander (TE) or implant reconstruction was evaluated by comparing a contemporary cohort of 611 patients in 2016–2018 with a historical cohort of 188 patients in 2010. Opioid use and LOS were compared over time and stratified by laterality, mastectomy type, axillary procedure, and reconstruction. Associations were assessed by uni- and multivariate analyses.

Results

In 2010, 95.2% of patients required intravenous (IV) opioids, with a last dose 15.5 h after completion of surgery, compared with 68.7% of patients in 2016–2018, with a last dose 1.8 h after surgery (p < 0.001). Patients prescribed gabapentin postoperatively were less likely to require inpatient IV or oral opioids (p < 0.001). The mean LOS decreased from 37 h in 2010 to 27.5 h in 2016–2018 without an increase in the readmission rate (6.9% vs. 4.1%; p = 0.112). Patients were more likely to stay more than one night if they were older (p = 0.012), had undergone bilateral mastectomies (p < 0.001) or TE reconstruction (p = 0.012), and had surgery in 2010 compared with 2016–2018 (p < 0.001). Even after adjustment for LOS, IV opioid use remained significantly associated with year of surgery (p < 0.001).

Conclusions

Compared with 2010, patients undergoing mastectomy with TE or implant reconstruction in 2016–2018 required less inpatient opioids and had decreased LOS. The authors attribute this to an enhanced recovery program focused on preoperative counseling, non-opioid analgesics, and improved surgical efficiencies.
Literature
1.
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16.CrossRefPubMed
2.
Poleshuck EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006;7:626–34.CrossRefPubMed
3.
Gassman AA, Yoon AP, Maxhimer JB, et al. Comparison of postoperative pain control in autologous abdominal free flap versus implant-based breast reconstructions. Plast Reconstr Surg. 2015;135:356–67.CrossRefPubMed
4.
Marcusa DP, Mann RA, Cron DC, et al. Prescription opioid use among opioid-naive women undergoing immediate breast reconstruction. Plast Reconstr Surg. 2017;140:1081–90.CrossRefPubMed
5.
Parikh RP, Sharma K, Guffey R, Myckatyn TM. Preoperative paravertebral block improves postoperative pain control and reduces hospital length of stay in patients undergoing autologous breast reconstruction after mastectomy for breast cancer. Ann Surg Oncol. 2016;23:4262–9.CrossRefPubMedPubMedCentral
6.
Terkawi AS, Tsang S, Sessler DI, et al. Improving analgesic efficacy and safety of thoracic paravertebral block for breast surgery: a mixed-effects meta-analysis. Pain Physician. 2015;18:E757–80.PubMed
7.
Tahiri Y, Tran DQ, Bouteaud J, et al. General anaesthesia versus thoracic paravertebral block for breast surgery: a meta-analysis. J Plast Reconstr Aesthet Surg. 2011;64:1261–9.CrossRefPubMed
8.
de Kok M, Dirksen CD, Kessels AG, et al. Cost-effectiveness of a short stay admission programme for breast cancer surgery. Acta Oncol. 2010;49:338–46.CrossRefPubMed
9.
Stone AB, Grant MC, Pio Roda C, et al. Implementation costs of an enhanced recovery after surgery program in the United States: a financial model and sensitivity analysis based on experiences at a quaternary academic medical center. J Am Coll Surg. 2016;222:219–25.CrossRefPubMed
10.
Boughey JC, Goravanchi F, Parris RN, et al. Improved postoperative pain control using thoracic paravertebral block for breast operations. Breast J. 2009;15:483–8.CrossRefPubMed
11.
Boughey JC, Goravanchi F, Parris RN, et al. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009;198:720–5.CrossRefPubMedPubMedCentral
12.
Kairaluoma PM, Bachmann MS, Korpinen AK, Rosenberg PH, Pere PJ. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy. Anesth Analg. 2004;99:1837–43, Table of Contents.
13.
Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2010;105:842–52.CrossRefPubMed
14.
Aufforth R, Jain J, Morreale J, Baumgarten R, Falk J, Wesen C. Paravertebral blocks in breast cancer surgery: is there a difference in postoperative pain, nausea, and vomiting? Ann Surg Oncol. 2012;19:548–52.CrossRefPubMed
15.
Bhuvaneswari V, Wig J, Mathew PJ, Singh G. Postoperative pain and analgesic requirements after paravertebral block for mastectomy: a randomized controlled trial of different concentrations of bupivacaine and fentanyl. Indian J Anaesth. 2012;56:34–9.CrossRefPubMedPubMedCentral
16.
Fahy AS, Jakub JW, Dy BM, et al. Paravertebral blocks in patients undergoing mastectomy with or without immediate reconstruction provides improved pain control and decreased postoperative nausea and vomiting. Ann Surg Oncol. 2014;21:3284–9.CrossRefPubMed
17.
Wolf O, Clemens MW, Purugganan RV, et al. A prospective, randomized, controlled trial of paravertebral block versus general anesthesia alone for prosthetic breast reconstruction. Plast Reconstr Surg. 2016;137:660e–6e.CrossRefPubMed
18.
Offodile AC II, Aycart MA, Segal JB. Comparative effectiveness of preoperative paravertebral block for post-mastectomy reconstruction: a systematic review of the literature. Ann Surg Oncol. 2018;25:818–28.CrossRefPubMed
19.
Coopey SB, Specht MC, Warren L, Smith BL, Winograd JM, Fleischmann K. Use of preoperative paravertebral block decreases length of stay in patients undergoing mastectomy plus immediate reconstruction. Ann Surg Oncol. 2013;20:1282–6.CrossRefPubMed
20.
Temple-Oberle C, Shea-Budgell MA, Tan M, et al. Consensus review of optimal perioperative care in breast reconstruction: enhanced recovery after surgery (ERAS) society recommendations. Plast Reconstr Surg. 2017;139:1056e–71e.CrossRefPubMed
21.
Offodile AC II, Gu C, Boukovalas S, et al. Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2019;173:65–77.CrossRefPubMed
22.
Batdorf NJ, Lemaine V, Lovely JK, et al. Enhanced recovery after surgery in microvascular breast reconstruction. J Plast Reconstr Aesthet Surg. 2015;68:395–402.CrossRefPubMed
23.
24.
Dumestre DO, Webb CE, Temple-Oberle C. Improved recovery experience achieved for women undergoing implant-based breast reconstruction using an enhanced recovery after surgery model. Plast Reconstr Surg. 2017;139:550–9.CrossRefPubMed
Metadata
Title
Enhanced Recovery Minimizes Opioid Use and Hospital Stay for Patients Undergoing Mastectomy with Reconstruction
Authors
Caroline J. McGugin, MD, MSPH
Suzanne B. Coopey, MD
Barbara L. Smith, MD, PhD
Bridget N. Kelly, BA
Carson L. Brown, MS
Michele A. Gadd, MD
Kevin S. Hughes, MD
Michelle C. Specht, MD
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 11/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07710-3

Other articles of this Issue 11/2019

Annals of Surgical Oncology 11/2019 Go to the issue

Hepatobiliary Tumors

Fibrinogen–Albumin Ratio Index (FARI): A More Promising Inflammation-Based Prognostic Marker for Patients Undergoing Hepatectomy for Colorectal Liver Metastases

Endocrine Tumors

Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database

Peritoneal Surface Malignancy

Standard Operating Procedures for Anesthesia Management in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improve Patient Outcomes: A Patient Cohort Analysis

Gastrointestinal Oncology

Is Additional Surgery Always Sufficient for Preventing Recurrence After Endoscopic Submucosal Dissection with Curability C-2 for Early Gastric Cancer?

Hepatobiliary Tumors

Resection of the Dorsal Sector of the Liver: The Anterior Transhepatic Approach

Gastrointestinal Oncology

Reply to “Utility of Intraoperative Margin Assessment by Frozen Section in Gastric Cancer”